Such a study design would provide more robust insights into the role of p53 and E-cadherin expression in bladder cancer progression and potentially inform the development of improved diagnostic and prognostic markers that could guide personalized treatment decisions and ultimately improve patient outcomes. This evidence concerns the gene CDH1 and urinary bladder cancer.